20th August 2009, London, UK, Logos Technologies, Inc. is holding its 2nd Annual face-to-face ‘ALPHADAS® User Group’ (AUG) meeting in October 2009, hosted by Spaulding Clinical Research at their comprehensive, leading Phase I Clinical trial facility.
“I am excited to host the AUG and to showcase our fully-automated, state-of-the-art clinic using ALPHADAS®” said Daniel Selness, Vice President of Operations at Spaulding Clinical and President of the AUG. “We have automated our site by seamlessly integrating ALPHADAS® with a host of systems, including Dynacare Laboratory and Mortara’s Surveyor 12-Lead Wireless ECG for near real-time electronic results,” continued Mr. Selness.
For more information on Spaulding Clinical, watch their video tour and see ALPHADAS® in action at their website: www.spauldingclinical.com
“We are very excited about this year’s event and are expecting an excellent turnout of ALPHADAS® users—which should include two of the top ten pharmaceuticals—plus Duke Clinical Research Unit, and a number of other key organizations,” said Jason Straber, Vice President of Logos Technologies, Inc. Jason is assisting in the facilitation of this year’s event.
The AUG meeting will be an excellent opportunity for users to experience a fully-automated site, listen to presentations, share experiences, network with peers, and learn about industry developments and the technology roadmap. Logos Technologies, Inc. will be introducing a wide range of services to accelerate implementations for new clients, accelerate timelines to upgrade existing clients, and offer operational support, such as study design and planning efforts within ALPHADAS®.
“We are pleased to announce that despite the recent internal changes within the Logos group, Logos Technologies Inc. now has the opportunity to provide our clients with an even higher level of service. We believe this will position us as a leader in Early Phase EDC and Phase I site automation,” said Giles Wilson, CEO of Logos Technologies, Inc. “Additionally, the imminent launch of our new client partnership program will add more value to our early Phase products and services, which, in turn, will bring great success and value to our clients and our marketplace.”
About Logos Technologies Inc.
Logos Technologies Inc is a leading provider of world-class integrated clinical trial solutions to the industry’s pharmaceutical, biotechnology and clinical research organisations. ALPHADAS® is an early Phase clinical trials system that is mobile, schedule-driven, and that provides proactive real-time eSource data collection.
